Virodhamine is involved in modulating the endocannabinoid system, primarily acting as an antagonist or weak partial agonist at the CB1 receptor while showing agonist activity at the CB2 receptor. This dual activity makes it a potential target for research in conditions involving endocannabinoid dysregulation. It has been studied for its role in mood regulation, suggesting possible relevance in anxiety and depression. Due to its ability to block CB1 receptors in the central nervous system while activating CB2 receptors peripherally, it may offer a pathway for developing treatments that avoid psychoactive effects while promoting anti-inflammatory responses. Research is ongoing into its potential therapeutic use in neurodegenerative diseases, immune modulation, and metabolic disorders.